Study title: Milano GM et al High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience Cancer. 2006 Apr 15;106(8):1838-45. Erratum in: Cancer. 2006 Sep 15;107(6):1421
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: ETOPOSIDE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |